Displaying results 1 - 12 of 4657
Cirrhosis & Complications
On-demand Webinars on Decompensated Cirrhosis • Description Decompensated cirrhosis affects over 10 million people worldwide and is the cause of mortality of about 2 million people yearly. Death rates remain largely unchanged, despite escalating healthcare costs. The clinical and prognostic models of decompensated cirrhosis have been studied extensively in the past 20 years, leading up to the identification of a newly defined clinical entity: acute-on chronic liver failure. Emerging data from studies on the pathophysiological basis of decompensated cirrhosis has identified systemic inflammation as being central to the progression of liver disease and mortality. This new understanding is leading to rapid changes in the approaches to the management of cirrhotic patients, design of clinical trials, and selection of patients for early liver transplantation. In recognition of the exciting new developments in the field, EASL and the Journal of Hepatology are planning to publish a special supplement summarising the current literature authored by leaders in the field. These two EASL webinars have been designed to allow the authors to critically discuss recent advances in decompensated cirrhosis with the audience.   Targeted Audience Hepatologists, gastroenterologists Transplant surgeons General practitioners Health care professionals   Learning Objectives Understand the changing epidemiology of cirrhosis Learn about new perspectives in the trajectory of cirrhosis and why acute on chronic liver failure should be considered a distinct clinical entity Understand the role of systemic inflammation and how this fits into the established pathophysiological mechanisms of decompensated cirrhosis Understand how the management of decompensated cirrhosis is changing, the concept of disease modifying agents and issue of working beyond guidelines How sarcopenia and frailty impact on outcomes, their assessment and therapeutic approaches Exploring nuances in the intensive care management of patients with ACLF and the role of liver transplantation   Webinar 1: Disease Trajectory and Pathophysiology This first webinar took place on 25.05.2021. Access the on-demand webinar here. Programme Time Title 18:00-18:05 Welcome and Introduction Rajiv Jalan, University College London Medical School, United Kingdom Gyongyi Szabo, Beth Israel Deaconess Medical Center, United States of America 18:05-18:20 Changing Epidemiology and Healthcare burden Peter Jepsen, University of Aarhus, Denmark 18:20-18:35 Disease Trajectory and New tools for stratification  Thierry Gustot, Université Libre de Bruxelles, Belgium 18:35-18:50 Pathophysiological basis of Decompensated Cirrhosis Jonel Trebicka, University Goethe Frankfurt am Main, Germany 18:50-19:05 Immune dysfunction in cirrhosis Shilpa Chokshi, Institute of Hepatology and Foundation for Liver Research, United Kingdom 19:05-19:30 Discussion and Q&A All   Webinar 2: Management and Liver Transplantation This second webinar took place on 01.06.2021.Access the on-demand webinar here. Programme Time Title 18:00-18:05 Welcome and Introduction Paolo Angeli, University of Padova, Italy Marina Berenguer, University of Valencia, Spain 18:05-18:20 Intensive Care Management William Bernal, Kings College London, United Kingdom 18:20-18:35 Established and Novel therapies for decompensated cirrhosis  Raj Mookerjee, University College London, United Kingdom 18:35-18:50 Assessment and management of  Sarcopenia and Frailty Puneeta Tandon, University of Alberta, Canada 18:50-19:05 Changing rules for transplanting patients with decompensated cirrhosis Patrizia Burra, University of Padova, Italy 19:05-19:30 Discussion and Q&A All
COVID-19 and the liver
COVID-19 vaccination in patients with liver disease webinar • Details The second of EASL's live webinars on COVID-19 addresses the topic of vaccination in patients with liver disease. This was chaired by Professor Ulrich Spengler and Professor Verena Keitel, who were joined by Dr Thomas Marjot, Professor Julian Schulze-zur-Wiesch, Professor Dr Miriam Sturkenboom and Professor Rifaat Safadi. Dr Marjot presented on the prioritizing liver disease patients for COVID-19 vaccination followed by an Overview of COVID-19 vaccines available in Europe presented by Professor Schulze-zur-Wiesch. Professor Sturkenboom presented the Benefit/risk of COVID-19 vaccinations: current knowledge and specific populations before Professor Safadi closed with the First practical experiences with COVID-19 vaccinations in Israeli patients with liver disease. A fascinating Q&A session after the main presentations covered a range of topics including how to monitor vaccine efficacy in liver disease patients, what needs to be done in countries with limited supply, whether COVID-19 vaccines can be combined with others and recommendations for specific patient profiles. Target Audience Hepatologists, gastroenterologists General practitioners Health care professionals Clinical scientists Basic scientists Learning Objectives Learn about the relative risk for severe COVID-19 in patients with chronic liver diseases (cirrhosis, metabolic and autoimmune liver disease, liver transplantation) as compared to other high-risk populations Learn about the efficacy and safety of current COVID-19 vaccines (mRNA vaccines, vector vaccines), their contraindications and limitations in patients with liver diseases Learn about the scientific rationale for currently recommended vaccination strategies concerning patients with liver diseases Learn about the first outcome data of population-based vaccination in patients with and without liver diseases   Programme Title Welcome & Introduction Ulrich Spengler, University of Bonn, Germany Verena Keitel, University Hospital of Düsseldorf, Germany Defining liver patients in urgent need of a COVID-19 vaccine for priorisation Thomas Marjot, University of Oxford, United Kingdom Overview of the COVID-19 vaccines available in Europe Julian Schulze-zur-Wiesch, University Medical Center Hamburg-Eppendorf, Germany Benefit/Risk of COVID-19 vaccinations: Current knowledge and how it translates to specific populations Miriam Sturkenboom, Julius Center Research Program Cardiovascular Epidemiology, Netherlands First practical experiences with COVID-19 vaccination in Israeli patients with liver disease Rifaat Safadi, Hadassah Medical Centers of the Hebrew, University Jerusalem, Israel Discussion and Q&A All   Watch the full on-demand webinar